Andrew R. Neill - 25 Aug 2025 Form 4 Insider Report for Shattuck Labs, Inc. (STTK)

Role: Chief Financial Officer
Signature: /s/ Andrew R. Neill
Issuer symbol: STTK
Transactions as of: 25 Aug 2025
Net transactions value: +$55,556
Form type: 4
Filing time: 27 Aug 2025, 06:30:06 UTC
Previous filing: 28 Jan 2025
Next filing: 13 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Neill Andrew R	Chief Financial Officer	C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN	/s/ Andrew R. Neill	27 Aug 2025	0001827204

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	STTK	Common Stock	Award	$55,556	+64,027	+37%	$0.8677	237,473	25 Aug 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	STTK	Warrants (Right to Buy)	Award		+64,027			64,027	25 Aug 2025	Common Stock	64,027	$1.08	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 64,027 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 64,027 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.
F2	The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.

Content

On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 64,027 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 64,027 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.

The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.